T form hematopoietic cells rests in the activation of downstream effectors that transmit the oncogenic signal from the cytoplasm to the nucleus.I4 One such effector is the protooncogene c-myc, which is required for BCR-ABL or V-ABL transformation of hematopoietic cells.536 The identification of downstream effectors of p210"r/ab' has raised the possibility of developing a combination therapy of chronic myelogenous leukemia (CML) based on targeting genes with distinct roles in the process of transformation. Antisense oligodeoxynucleotides have been extensively used in the past years in vitro and in animal models of human malignancies as a biological tool to assess oncogene function and as potential therapeutic agents.'." Thus, we undertook experiments to compare the effects of phosphorothioate bcr-ab1 and cmyc antisense oligodeoxynucleotides, alone and in combination, in vitro and in immunodeficient SCID mice carrying primary blast cells from a patient with CML-blast crisis (CML-BC). Primary CML-BC cells were used because of our previous studies indicating that in vitro colony formation of these cells was inhibited more efficiently than that of CML chronic phase cells by bcr-ab1 ODNS.'*,'~ Systemic injection of phosphorothioate bcr-ab1 antisense oligodeoxynucleotides into SCID mice carrying the BV173 Philadelphia' cell line retarded the disease process and prolonged the survival of leukemic mice." However, the proliferation of BV173 and other Philadelphia' cell lines was affected in vitro by certain bcr-ab1 oligodeoxynucleotides designed to serve as contr01s.'~ Although the nonspecific effects were more evident when BV173 cells were cultured at low density in the presence of bcr-ab1 [S]ODNS,'~ it remains possible that some of the in vivo effects might have been sequenceindependent. Such sequence-independent effects of [SIODNs might be caused by sequence-independent binding to a variety of intra-and extracellular proteins in mono-or multimeric
We report here that only bcr-ab1 oligodeoxynucleotides specifically targeting bcr-ab1 hybrid transcripts suppress the disease process in mice injected with CML-BC primary cells. Furthermore, the combination with c-myc antisense ODNs further enhances the survival of these leukemic mice, showing the potential of such an approach for the treatment of Philadelphia' leukemias.
MATERIALS AND METHODS

Cells.
Normal bone marrow (BM) and CML-BC cells were obtained by aspiration from the iliac crest of healthy volunteers and from the peripheral blood (PB) of patients (Department of Hematology-Oncology, Thomas Jefferson University, Philadelphia, PA), respectively, after informed consent. Cells were processed as described!.'* Patient cells used for injection in SCID mice (see below) were karyotypically characterized and found to contain, in addition to the Philadelphia chromosome (b2/a2 breakpoint), a 16q-abnormality with breakpoint in the q12.2-q13 region in 75% of the metaphases. Trisomy of chromosomes 4, 8, and 13 was found in 15% of the metaphases. Sequence analysis of the p53 coding sequence (cDNA and exon-intron junction amplification) did not reveal any point mutation.
ODNs were prepared on an Applied Biosystems model 380B or 3902 automated synthesizer (Lynx Therapeutics Inc, Hayward, CA). The following phosphorothioate [SIODNs were used for the in vitro antisense experiments: (1) 16 mer bUa2 antisense sequence (AAGGGC'ITC'ITCC'ITA), containing 8 nucleotides each complementary to the BCR exon 2 and the ABL exon 2 portion, respectively; (2) 16 mer b3/a2 antisense sequence (AAGGGCTTTTGAACTG), containing 8 nucleotides each complementary to the BCR exon 3 and the ABL exon 2 portion, respectively; (3) 16 mer b2/a2 sense sequence (TAAGGAA GAA-GCCC'IT); (4) 15 mer c-myc antisense sequence (AACG'ITGAG-GGGCAT), complementary to the translation initiation codon and downstream sequences of the human c-myc mRNA; (5) 15 mer cmyc sense sequences (ATGCCCCTCAACG'IT), corresponding to the translation initiation codon and downstream sequences of c-myc "A; (6) 15 mer c-myc scrambled sequence (AAGCATACG-GGGTGT), containing the "G quartet" motif; (7) 18 mer myeloperoxidase antisense sequence (AGAGAAGAAGGGAACCCC), complementary to nucleotides for codons 2-7 of the myeloperoxidase mRNA. Oligodeoxynucleotides used for reverse transcription-polymerase chain reaction (RT-PCR) detection of BCR-ABL and P-actin transcripts in mouse tissues are as follows: (1) [SIODNs were added at the beginning of the culture (40 pg/mL) and again (at 50% of the initial dose) 24 and 48 hours later. For protein analysis, cells were centrifuged on Histopaque-1077, washed, and solubilized in RIPA lysis buffer containing 10% deoxycholate, 2% NP-40, 0.2% SDS, and 10% glycerol, in Tris-buffered saline (TBS), pH 7.2. Proteins (from lo6 cells/sample) were separated on 7.5% SDS-PAGE and transferred to nitrocellulose (MCI, Westboro, MA). Filters were blocked in 0.5% gelatin in TBS and then sequentially incubated with murine monoclonal anti-ABL antibody (kind gift of Dr R. Arlinghaus, MD Anderson Medical Center, Houston, TX), anti-c-MYC antibody (Oncogene Science Inc, Uniondale, NJ). The murine monoclonal anti-HSP 72/73 (Oncogene Science) and anti-c-Myb antibody (UBI, Lake Placid, NY) were used as controls for protein loading. Filters were washed five times with 0.25% Tween, 0.25% NP-40 in TBS buffer, and blotted with anti-murine polyclonal antibody linked to horseradish peroxidase (Amersham Corp, Arlington Heights, IL). Proteins were detected using the ECL Western blotting detection system (Amersham).
[YODNs treatment of CML-BC primary cells in vivo. Outbred (7-to 9-week-old) ICR-SCID male mice (Taconic, Germantown, NY) were used. According to the vendor, the frequency of "leaky" SCID mice in the population is <1%. SCID mice were inoculated intravenously with lo7 CML-BC primary cells (UPNI) and 3 weeks later treated intravenously with [SIODNs (0.2 mL of RPMI 1640 medium, bolus injection) at 1 mg/d for 12 consecutive days. In the combination groups, different [SIODNs were injected on alternate days. Control mice received diluent only. PB leukocytes (PBL), splenocytes (SPL), BM cells (BMC), and liver cells (LIV) were isolated after 8 weeks of leukemia growth and analyzed for the presence of leukemic cells by flow cytometry (CD45 antigen present on human but not murine leukocytes), clonogenic assay (leukemia-colony forming cells), and RT-PCR (detection of bcdabl transcript) as described.'* Total RNA was extracted from lo6 cells procured from various organs, as described." RNA from each group was reverse transcribed using 400 U of Moloney murine leukemia virus reverse transcriptase (BRL, Gaithersburg, MD) and 5 X lo-' U of random hexamers (Boehringer Mannheim, Germany) for 1 hour at 37°C. The resulting cDNA was divided into two aliquots and amplified with 5 U of Taq polymerase (Boehringer Mannheim, Indianapolis, IN) in the presence of the 5' primer of bcr exon 2 and the 3' primer c-ab1 exon 2, or of the 5' and 3' primers of P-actin, generating a 257-bp BCWABL fragment corresponding to the junction region, and a 210-bp p-actin fragment, respectively. After 2.5 cycles of PCR, an additional 5 U of Taq polymerase was added and the reaction was performed for an additional 2.5 cycles. Reaction products were electrophoresed in 2% agarose gel, transferred to Zeta-probe blotting membranes (Bio-Rad Laboratories, Richmond, CA) and hybridized overnight at 50°C using the ab1 exon 2 or P-actin probes end-labeled with [y-'*p]ATP and polynucleotide kinase as described.I2 Filters were washed twice with 2 X SSC + 0.1% sodium dodecyl sulfate (SDS) at 49°C for 30 minutes and exposed to X-ray films.
RT-PCR detection of BCR-ABL transcripts in mice tissues.
RESULTS
Effects of bcr/abl andor c-myc antisense [SIODNs on CML-BCprimary cells.
In vitro colony formation of CML-BC primary cells was partially inhibited after incubation with bcr/abl junction-specific antisense [SIODNs (b2Ja2 or b3/a2) or by c-myc antisense [SIODNs at optimal concentrations (80 pg/mL each) ( Table 1) ; in combination, the bcr/abl + c-myc antisense [SIODNs, used in a final concentration identical to that of single antisense [SIODNs, inhibited proliferation 2.5 to 7 times more effectively than the individual antisense [SIODNs (Table 1) . c-myc sense [SIODNs and bcr/abl junction-nonspecific antisense [SIODNs were noninhibitory at the concentrations tested, and when used in combination did not exert any synergistic antileukemic effect. CML-BC marrow cells from UPNl (selected for injection in SCID mice) were also exposed to a 16 mer b2/a2 sense [SIODN, a 15 mer c-myc scrambled "G quartet" [SIODN, or an 18 mer myeloperoxidase antisense [SIODN, individually or in combination with either the c-myc or the bcr-ab1 b2la2 antisense sequence. None of these sequences had a toxic effect at the concentrations tested (Table 1) . c-myc antisense [SIODNs, alone or in combination with bcr/abl [SIODNs, had no effect on colony formation from normal marrow progenitors (Table 2) . Inhibition of CML-BC cell proliferation by bcr/abl junction-specific or c-myc antisense [SIODNs was accompanied by downregulation of BCWABL or c-MYC protein levels, respectively (Fig 1) . The combined treatment downregulated both BCWABL and c-MYC protein (Fig 1) . Levels of HSP 72/73 and Myb protein were unaffected. Since the half-life of c-Myb protein is very short (10 to 30 minute^),'^.'^ the lack of effects on c-Myb levels argues against a nonspecific inhibition of cell growth.
Effects of bcr/abl, c-myc, or bcr/abl + c-myc antisense
[SIODNs on leukemia progression in SCID mice. We assessed the antileukemic effects of bcr-ab1 and c-myc [SIODNs, alone and in combination, in immunodeficient SCID mice (males, 7 to 9 weeks old, 20 to 22 g) injected intrave- nously (IV) with lo7 CML-BC primary cells ( "1) .
Pri-
mary cells from UPNl were selected because of their ability to form a high number of growth factor-independent colonies, and the sensitivity to treatment with specific [SIODNs ( Table 1) . Injection of lo7 cells induced, reproducibly, a disease process reminiscent of that in humans, with initial infiltration of hematopoietic tissues and subsequent spread to nonhematopoietic organs. Twenty one days later, mice were systemically injected for 12 consecutive days with 1 mgidmouse of b31a2 AS and c-myc S (6 days each, every other day), bUa2 AS, c-myc AS, or bUa2 AS and c-myc AS (6 days each, every other day). Control mice were injected with diluent only. Eight weeks after injection of leukemic cells, the disease process was examined in three mice from each group by immunofluorescence, colony assay, and RT-PCR using RNA of various tissues. Immunofluorescence assay detected CD45+ cells in BM of control, b3/a2 junction-nonspecific AS, and c-myc S-treated mice, and also at very low frequency in c-myc AS [SIODN-treated mice, but not in mice treated with bWa2 junction-specific AS or b2f a2 AS and c-myc AS (Table 3 ). The more sensitive clonogenic assay revealed the development of leukemic colonies from spleen suspensions, and, with higher frequency, from BMC of control and c-myc sense + b3la2 AS [SIODNtreated mice; in contrast, cell suspensions of c-myc or b2/ a2 antisense-treated mice contained far fewer clonogenic cells (Table 3) . Only one of the mice treated with both bU a2 + c-myc AS ODNs contained detectable clonogenic leukemic cells. RT-PCR amplification of bcr-ab1 transcripts in RNA isolated from various tissues of control and c-myc sense + b3/a2 antisense [SIODN-treated animals (three micdgroup) revealed bcr-ab1 transcripts in each of these tissues (Fig 2) . Bcr-ab1 transcripts were also detected in all examined tissues of mice treated with individual antisense [SIODNs, but the signal was much weaker than that observed in the tissues of control mice. Even weaker signals or no signals were detected in the RNA isolated from all of the examined organs of mice injected with bUa2 + c-myc AS [SIODNs, suggesting that the leukemic cell load in mice treated with the [SIODNs combination was reduced as compared with that of mice treated with individual ODNs. Comparable amounts of &actin detected in each group of organs indicated the integrity and the similar loading of the amplified products. These results are consistent with those obtained by immunofluorescence and clonogenic assays. Such differences among the groups of mice were reflected in their mortality rates (Fig 3) : all 10 control and 10 b31a2 antisense + c-myc sense [SIODN-treated mice died with diffuse leukemia, as confirmed by necropsy (Fig 4) Thus, the combination of bcr-ab1 junction-specific (b2/a2) antisense ODNs and c-myc antisense ODNs inhibited the expression of BCWABL oncogenic tyrosine kinase and c-MYC protooncogene, and exerted synergistic antitumor effects that were much more effective than those achieved by the same doses of individual antisense ODNs.
In vitro effects of bcr/ahl andor c-myc antisense ODNs on CML-BC cells recovered after in vivo antisense ODNs therapy. The inability of the [SIODNs, individually or in combination, to completely eradicate leukemia in SCID mice most likely reflects the insufficient delivery of these agents to the leukemic cells in vivo, but could also be due to distinct biologic properties of leukemic cells that could result in the emergence of clones with an ODN-resistance phenotype.
To assess the latter possibility, terminally ill mice (2 per group), previously treated with antisense ODNs. were killed and the sensitivity of BM and spleen cells to the antisense ODNs treatment was analyzed in vitro in clonogenic assays conducted in the absence of hematopoietic growth factors to allow growth factor-independent colony formation from human leukemic cells only.'2 As indicated in Table 4 , colony formation from leukemic cells that survived the in vivo antisense therapy was inhibited by treatment with c-myc and/or brc-ab1 antisense [SIODNs.
DISCUSSION
In the present study we assessed whether antisense ODNs targeting the bcr-ab1 transcript junction could delay the leukemic disease process in SCID mice injected with CML-BC primary cells, and whether the combination with c-myc AS ODNs enhances the therapeutic potential of the antisense strategy in the treatment of Philadelphia' leukemias.
We recently reported that systematically injected 26-mer b2/a2 antisense [SIODNs suppress temporarily the disease process in SCID mice harboring BV173 Philadelphia' cells." However, the use of a 26-mer sequence able to hybridize partially with the normal c-ab1 mRNA (manuscript in preparation) and the reported sequence-independent effects of certain bcr-ab1 ODNs on the BV173 line,I4 prompted us to investigate the therapeutic effect of junction-specific bcr-ab1 ODNs on CML-BC primary cells growing in SCID mice. In agreement with our previous studies,'' we found that the disease process was delayed by the junction-specific 16-mer b2/a2 ODNs, but not by the 16-mer b3/a2 ODNs, as reflected by reduction of the leukemic load in mouse tissues and prolongation of survival. Such effects correlated with the ability of the b2/a2 16-mer ODNs (but not the b3/a2 16-mer sequence) to downregulate the expression of the p2 IOhcr'ah' protein in vitro (Fig 1) . The partial therapeutic effect of the 16-mer b2/a2 ODNs likely reflects the inefficient uptake of ODNs by leukemic cells in vitro and in vivo20.2'; furthermore, [SIODNs are not uniformly distributed in mouse tissues, with a preferential recovery of intact [SIODNs from liver and kidney but, at much lower levels, from hematopoietic tissues such as bone marrow and spleen.". 22 We also considered the possibility that the prolonged treatment with systemically injected ODNs might have induced the emergence of leukemic clones with intrinsic resistance to such agents. However, colony formation of leukemic cells isolated from terminally ill mice after the full course of [SIODNs treatment was still greatly diminished by b2/a2 antisense ODNs ( Table  4 ). suggesting that potential development of "ODN resistance" is not a primary factor in determining the therapeutic response in systematically treated leukemic mice, at least after a single course of therapy. Thus, repeated courses of Bcr-ab1 and p-actin transcripts were separately detected by RT-PCR using total RNA from 5 x I O 5 cells for each tissue sample, 56 days after leukemia implantation. Blots were hybridized with a yI'ZPl-end labeled c-ab1 or p-actin oligomer contained in the amplified 257 bp bcr-ab1 or 210 bp p-actin segment, respectively. Blots were exposed for 24 hours (bcr-abl) and 2 hours (p-actin), respectively. The blot is representative of three different experiments using three mice (1,2, and 3) per group. For personal use only. on September 13, 2017 . by guest www.bloodjournal.org From Accordingly, it appears unlikely that this antitumor mechanism is an explanation for all of the in vivo effects described here. [SIODNs containing the CpG motif' may also stimulate interferons and augment NK cell activity?' Once again, it is unlikely that our findings can be explained by postulating the involvement of this mechanism, as the CpG motif is not present in the bcdabl ODNs, whereas it is present in both the c-myc sense and antisense sequences. Nevertheless, nonspecific antiproliferative effects might be due to as yet unknown motifs, as pointed out recently? ' However, the nonspecific effects we have considered as Alternatively, the downregulation of gene expression by individual antisense [SIODNs at the relatively low concentrations reached in vivo",u might be insufficient to inhibit cell proliferation, whereas "partial" inhibition of two cooperating oncogenes might induce a more permanent block in the ability to proliferate.
It is unlikely that such a combination ODN approach will be restricted to the targeting of bcr-ab1 and c-myc. Because several downstream effectors of ~2 1 0~'~~' have been recently identified,I4 it would be interesting to compare therapeutic responses associated with the targeting of either cytoplasmic and nuclear effectors, or cytoplasmic or nuclear effectors only.
In principle, a combination antisense ODN therapy of Philadelphia' leukemias should be based on targeting bcr-ab1 transcripts because of the pathogenetic role of the encoded p r~t e i n~' "~ and its selective presence in leukemic cells. The downstream effectors of ~2 1 0~'~~' are not leukemia-specific and therefore the consequences of targeting such genes for the proliferation of normal cells must be considered. Antisense oligodeoxynucleotides targeting c-myc had no apparent effect on the colony-forming ability of normal progenitor cells35 (Table 2 ). In agreement with these findings, use of a dominant negative c-myc construct blocked proliferation of bcr-abl-transformed fibroblasts, but did not affect noma1 cells? Finally, control mice injected with murine c-myc antisense [SIODNs revealed no toxicity-associated morphologic changes in the organs examined and no decrement in the proliferation capacity of BMC as indicated by clonogenic assays (not shown). Together, these studies suggest that the targeting of bcr-ab1 and c-myc spares most or all normal cells, while affecting leukemic cells.
The synergistic antileukemic effect shown here is similar to that observed for combined chemotherapy, in which different drugs are designed to target tumor cells as they progress through distinct cell cycle stages. However, the promise of antioncogene therapy rests in the potential selectivity for disease-inducing agents, an essential condition for devising more effective anticancer treatments.
